156 related articles for article (PubMed ID: 24993015)
1. Cetuximab inhibits cisplatin-induced activation of EGFR signaling in esophageal squamous cell carcinoma.
Kwon J; Yoon HJ; Kim JH; Lee TS; Song IH; Lee HW; Kang MC; Park JH
Oncol Rep; 2014 Sep; 32(3):1188-92. PubMed ID: 24993015
[TBL] [Abstract][Full Text] [Related]
2. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
[TBL] [Abstract][Full Text] [Related]
3. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice.
Gong JH; Liu XJ; Li Y; Zhen YS
Cancer Chemother Pharmacol; 2012 May; 69(5):1323-32. PubMed ID: 22311160
[TBL] [Abstract][Full Text] [Related]
4. Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines.
Fukuoka S; Kojima T; Koga Y; Yamauchi M; Komatsu M; Komatsuzaki R; Sasaki H; Yasunaga M; Matsumura Y; Doi T; Ohtsu A
Oncotarget; 2017 Feb; 8(7):11020-11029. PubMed ID: 28038457
[TBL] [Abstract][Full Text] [Related]
5. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of EIF5A2, via hypoxia or gene amplification, contributes to metastasis and angiogenesis of esophageal squamous cell carcinoma.
Li Y; Fu L; Li JB; Qin Y; Zeng TT; Zhou J; Zeng ZL; Chen J; Cao TT; Ban X; Qian C; Cai Z; Xie D; Huang P; Guan XY
Gastroenterology; 2014 Jun; 146(7):1701-13.e9. PubMed ID: 24561231
[TBL] [Abstract][Full Text] [Related]
7. Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells.
Yoshioka M; Ohashi S; Ida T; Nakai Y; Kikuchi O; Amanuma Y; Matsubara J; Yamada A; Miyamoto S; Natsuizaka M; Nakagawa H; Chiba T; Seno H; Muto M
J Exp Clin Cancer Res; 2017 Aug; 36(1):101. PubMed ID: 28764725
[TBL] [Abstract][Full Text] [Related]
8. eIF4E promotes tumorigenesis and modulates chemosensitivity to cisplatin in esophageal squamous cell carcinoma.
Liu T; Li R; Zhao H; Deng J; Long Y; Shuai MT; Li Q; Gu H; Chen YQ; Leng AM
Oncotarget; 2016 Oct; 7(41):66851-66864. PubMed ID: 27588477
[TBL] [Abstract][Full Text] [Related]
9. Galectin-3 knockdown increases gefitinib sensitivity to the inhibition of EGFR endocytosis in gefitinib-insensitive esophageal squamous cancer cells.
Cui G; Cui M; Li Y; Liang Y; Li W; Guo H; Zhao S
Med Oncol; 2015 Apr; 32(4):124. PubMed ID: 25788032
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo.
Hara F; Aoe M; Doihara H; Taira N; Shien T; Takahashi H; Yoshitomi S; Tsukuda K; Toyooka S; Ohta T; Shimizu N
Cancer Lett; 2005 Aug; 226(1):37-47. PubMed ID: 16004931
[TBL] [Abstract][Full Text] [Related]
11. The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin.
Zhao L; Li QQ; Zhang R; Xi M; Liao YJ; Qian D; He LR; Zeng YX; Xie D; Liu MZ
Tumour Biol; 2012 Aug; 33(4):1115-23. PubMed ID: 22389159
[TBL] [Abstract][Full Text] [Related]
12. RUNX3 reverses cisplatin resistance in esophageal squamous cell carcinoma via suppression of the protein kinase B pathway.
Li DJ; Shi M; Wang Z
Thorac Cancer; 2016 Sep; 7(5):570-580. PubMed ID: 27766776
[TBL] [Abstract][Full Text] [Related]
13. Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.
Hou W; Qin X; Zhu X; Fei M; Liu P; Liu L; Moon H; Zhang P; Greshock J; Bachman KE; Ye BC; Wang H; Zang CY
Oncol Rep; 2013 Aug; 30(2):707-14. PubMed ID: 23708506
[TBL] [Abstract][Full Text] [Related]
14. Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents.
Knecht R; Peters S; Adunka O; Strebhardt K; Gstoettner W; Hambek M
Anticancer Res; 2003; 23(3B):2577-83. PubMed ID: 12894544
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
Kim EM; Mueller K; Gartner E; Boerner J
J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
[TBL] [Abstract][Full Text] [Related]
16. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
17. Targeting MCL-1 sensitizes human esophageal squamous cell carcinoma cells to cisplatin-induced apoptosis.
Yu X; Li W; Xia Z; Xie L; Ma X; Liang Q; Liu L; Wang J; Zhou X; Yang Y; Liu H
BMC Cancer; 2017 Jun; 17(1):449. PubMed ID: 28659182
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor activity of cetuximab and namitecan in human squamous cell carcinoma models relies on cooperative inhibition of EGFR expression and depends on high EGFR gene copy number.
De Cesare M; Lauricella C; Veronese SM; Cominetti D; Pisano C; Zunino F; Zaffaroni N; Zuco V
Clin Cancer Res; 2014 Feb; 20(4):995-1006. PubMed ID: 24327272
[TBL] [Abstract][Full Text] [Related]
19. Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines.
Kondo N; Tsukuda M; Sakakibara A; Takahashi H; Hyakusoku H; Komatsu M; Niho T; Nakazaki K; Toth G
Int J Oncol; 2012 Jun; 40(6):1805-12. PubMed ID: 22344385
[TBL] [Abstract][Full Text] [Related]
20. Metformin inhibited esophageal squamous cell carcinoma proliferation in vitro and in vivo and enhanced the anti-cancer effect of cisplatin.
Wang F; Ding X; Wang T; Shan Z; Wang J; Wu S; Chi Y; Zhang Y; Lv Z; Wang L; Fan Q
PLoS One; 2017; 12(4):e0174276. PubMed ID: 28406985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
